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Objective: Gray matter (GM) atrophy occurs in all multiple sclerosis (MS) phenotypes. We investigated whether there
is a spatiotemporal pattern of GM atrophy that is associated with faster disability accumulation in MS.
Methods: We analyzed 3,604 brain high-resolution T1-weighted magnetic resonance imaging scans from 1,417 par-
ticipants: 1,214 MS patients (253 clinically isolated syndrome [CIS], 708 relapsing-remitting [RRMS], 128 secondary-
progressive [SPMS], and 125 primary-progressive [PPMS]), over an average follow-up of 2.41 years (standard devia-
tion [SD] 5 1.97), and 203 healthy controls (HCs; average follow-up 5 1.83 year; SD 5 1.77), attending seven Euro-
pean centers. Disability was assessed with the Expanded Disability Status Scale (EDSS). We obtained volumes of the
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deep GM (DGM), temporal, frontal, parietal, occipital and cerebellar GM, brainstem, and cerebral white matter. Hier-
archical mixed models assessed annual percentage rate of regional tissue loss and identified regional volumes associ-
ated with time-to-EDSS progression.
Results: SPMS showed the lowest baseline volumes of cortical GM and DGM. Of all baseline regional volumes, only
that of the DGM predicted time-to-EDSS progression (hazard ratio 5 0.73; 95% confidence interval, 0.65, 0.82; p <
0.001): for every standard deviation decrease in baseline DGM volume, the risk of presenting a shorter time to EDSS
worsening during follow-up increased by 27%. Of all longitudinal measures, DGM showed the fastest annual rate of
atrophy, which was faster in SPMS (–1.45%), PPMS (–1.66%), and RRMS (–1.34%) than CIS (–0.88%) and HCs (–0.94%;
p < 0.01). The rate of temporal GM atrophy in SPMS (–1.21%) was significantly faster than RRMS (–0.76%), CIS (–
0.75%), and HCs (–0.51%). Similarly, the rate of parietal GM atrophy in SPMS (–1.24-%) was faster than CIS (–0.63%)
and HCs (–0.23%; all p values <0.05). Only the atrophy rate in DGM in patients was significantly associated with dis-
ability accumulation (beta 5 0.04; p < 0.001).
Interpretation: This large, multicenter and longitudinal study shows that DGM volume loss drives disability accumula-
tion in MS, and that temporal cortical GM shows accelerated atrophy in SPMS than RRMS. The difference in regional
GM atrophy development between phenotypes needs to be taken into account when evaluating treatment effect of
therapeutic interventions.
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The clinical course of multiple sclerosis (MS) is het-erogeneous. Some patients experience relapses with
recovery (relapsing-remitting [RR] MS), whereas others
develop progressive disability either from the onset (pri-
mary-progressive [PP] MS), or after a period of relapses
(secondary-progressive [SP] MS). RRMS patients account
for approximately 90% of cases at onset,1 whose majority
later progress to SPMS. The pathogenic mechanisms
driving accrual of disability are beginning to be eluci-
dated2: Neurodegeneration plays a crucial role in deter-
mining accrual of disability over time.3
Neurodegeneration is reflected in vivo by reduced
brain volume (or brain atrophy), which can be measured
by magnetic resonance imaging (MRI).3 Over time, brain
volume declines more rapidly in MS patients when com-
pared to age-matched healthy controls (HCs).3–6 Across
MS phenotypes, SPMS shows the fastest annual rate of
brain atrophy, which is estimated to be 0.6% (compared
to around 0.2% in age-matched HCs).5 The role of
brain atrophy in monitoring response to treatments in
MS is evolving: Whole brain atrophy has been recently
used as a primary outcome measure in phase II clinical
trials in SPMS.7,8
Whole brain atrophy is mainly driven by neuroaxo-
nal loss in the gray matter (GM).3 GM volume loss is
associated with long-term disability9,10 and explains phys-
ical disability better than white matter9,11 and whole
brain atrophy.5 Some GM regions, such as the cingulate
cortex and thalamus, are affected by volume loss more
extensively than others,12,13 and the extent of their vol-
ume loss correlates with disability13,14 and cognitive
impairment.15 Regional predilection for atrophy is not
unique to MS; for example, hippocampal atrophy is
more pronounced than the whole brain atrophy in the
early phase of Alzheimer’s disease (AD).16 Although
cross-sectional studies have previously shown patterns of
regional atrophy in different types of MS,12,17 studies on
longitudinal evolution of atrophy in different structures
across MS phenotypes are scarce.
The overarching goal of our study was to investigate
whether there is a spatiotemporal pattern of GM atrophy
that is associated with faster disability accumulation in
MS. In a large, multicenter cohort, which included all MS
phenotypes and HCs, we tested the following hypotheses:
(1) Some GM regions show faster atrophy rate than others
and their rate may differ between MS phenotypes; (2)
smaller baseline volumes of brain structures, reflecting a
more extensive neurodegeneration, predict disability
accrual; and (3) the rate of regional volume loss is associ-
ated with the rate of disability accumulation.
Patients and Methods
Participants
In this retrospective study, we collected data from seven Euro-
pean MS centers (MAGNIMS: www.magnims.eu) from 1,424
participants who have been studied between 1996 and 2016;
we included participants who fulfilled the following criteria: (1)
a diagnosis of MS according to 2010 McDonald Criteria18 or a
clinically isolated syndrome (CIS)19; (2) HCs without history
of neurological or psychiatric disorders; (3) at least two MRI
scans acquired with a minimal interval of 6 months with identi-
cal protocol, including high-resolution T1-weighted MRI
(allowing regional gray and white matter segmentation), and
T2/fluid-attenuated inversion recovery (FLAIR), sequences.
Patients were scored on the Expanded Disability Status Scale
(EDSS).20 To increase the number of HCs scans, which were
provided by four centers, we collected data from age-matched
HCs from the Parkinson’s Progression Marker’s Initiative
(PPMI; http://www.ppmi-info.org/data).
MRI scans were taken under consent obtained from each
subject independently in each center. The final protocol for this
study was reviewed and approved by the European MAGNIMS
collaboration for analysis of pseudo-anonymized scans.
ANNALS of Neurology
2 Volume 00, No. 00
Image Acquisition
We included scans from 13 different MRI protocols; all centers
except one provided three-dimensional (3D)/T1-weighted scans
(Supplementary Tables 1 and 2 show the MRI protocols).
Image Analysis
We performed image analysis as follows.
BIAS FIELD CORRECTION. We used N4 bias field correction
to correct for field inhomogeneity in T1-weighted scans using
ANTs v2.10.21
LESION FILLING. Lesion masks were manually delineated on
PD/T2 images by different raters at each center semiautomati-
cally, except for three centers that used the same automatic
lesion segmentation with LST toolbox (version 2.0.15).22 We
calculated linear transformation matrices to register T2/FLAIR
with the T1-weighted scan using FSL-FLIRT v5.0.23 Then, we
applied these matrices to lesion masks to transfer them into the
accompanying T1 subject space. We used the FSL lesion filling
method, which uses a white matter mask calculated with FSL-
FAST24 to fill T1 hypointensities within normal-appearing
whiter matter, so as to reduce segmentation errors, as previously
done.25–27
SYMMETRIC WITHIN-SUBJECT REGISTRATION. To avoid
asymmetric registration and interpolation of longitudinal scans
(eg, toward the baseline scan), we constructed an unbiased
subject-specific template that has “equal distance” from each time
point using FreeSurfer version 5.3.28–30 We linearly transformed
T1-weighted images to this symmetric space with the unbiased
transformation matrix for each time point and used cubic B-
spline interpolation to reduce interpolation artefacts. We manu-
ally checked the alignment of scans in the symmetric space.
TISSUE SEGMENTATION. Next, in the symmetric space, we
segmented T1 scans into the GM, white matter, and cerebro-
spinal fluid (CSF) with the Geodesic Information Flow (GIF)
software (part of NifySeg: http://cmictig.cs.ucl.ac.uk/niftyweb/
program.php?p5GIF),31 and parcellated each hemisphere into
regions of interest according to the Neuromorphometric
atlas.32 GIF uses an atlas propagation and label fusion strategy
to calculate the voxel probabilities of GM, white matter, and
CSF31; this method has been previously used in MS and other
neurodegenerative disorders.33,34 The template library had 95
MRI brain scans (HCs and patients with AD) with neuroana-
tomic labels (http://www.neuromorphometrics.com/). This
atlas, which is similar to the Mindboggle atlas, was developed
to improve the consistency and clarity of the Desikan-Killiany
protocol.32
To calculate brain masks and exclude segmentation errors
outside of the brain, we used STEPS (Similarity and Truth Esti-
mation for Propagated Segmentations, http://cmictig.cs.ucl.ac.
uk/niftyweb/program.php?p5BRAIN-STEPS) based on a tem-
plate library of 682 hand-drawn brain masks.35,36 These maps
were applied to each time point separately.
REGIONAL VOLUME CALCULATION. We visually assessed
the segmentations to assure the quality for statistical analysis.
To calculate regional volumes, we summed the probability of
the segmented tissue voxels (GM or white matter) in each par-
cellated region and multiplied the sum with the voxel volume.
We averaged values between left and right hemispheres. Next,
we summarised the regional volumes according to Neuromor-
phometrics protocol by summing the volume of GM regions in
the temporal, parietal, occipital, frontal lobes, cerebellum, and
deep GM (DGM; thalamus, putamen, globus pallidus, caudate,
and amygdala). We also obtained the volume of the brainstem
and of the cerebral white matter.
Figure 1 shows the image analysis pipeline.
Statistical Analysis
BRAIN VOLUMES AT BASELINE AND RATES OF VOLUME
CHANGES OVER TIME. To investigate baseline volumes (inter-
cept) and rates (slopes) of volume change by subject group and
region, we used linear mixed-effects models with the volume at a
given time as the response variable, and time and interactions with
time as fixed-effect covariates.37 This model estimates adjusted rate
FIGURE 1: Image analysis pipeline. An unbiased symmetric image registration approach was used to calculate atrophy. [Color
figure can be viewed at www.annalsofneurology.org]
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while allowing for nested correlation structures, such as time of
visit within subject within scanner, by incorporating, in this exam-
ple, subject and scanner random intercepts, and a random slope on
time. The interaction terms with time (eg, subject group 3 time)
allows the estimation of rate differences across the interacting vari-
able, in this example subject groups or clinical phenotypes. Includ-
ing another interaction with time, such as sex 3 time, adjusts the
rate for gender. In addition to time, the fixed-effect covariates
were: scanner magnetic field, subject group, sex, age at baseline,
and total intracranial volume (sum of the volumes of GM, WM,
and CSF) at baseline; and the interactions of each of these with
time. Disease duration was too highly correlated with age at base-
line to give reliable estimation and was omitted from the final
models. To estimate the percentage changes per unit (year) increase
in time, we log-transformed the volume.38 We adjusted time to
zero for those visits in which a patient converted from one pheno-
type to another (eg, CIS to RRMS). We performed post-hoc analy-
ses to identify specific GM regions within the cerebral lobes and
among the DGM nuclei that showed significant differences
between MS phenotypes, as well as the default-mode network
regions.39
To investigate whether there is an association between the rate
of loss in specific regions and MS phenotypes, three-way interactions
were used, for example, clinical phenotype3 region3 time.We used
R (version 3.2.2; R Foundation for Statistical Computing, Vienna,
Austria) and theNLMEpackage.40,41
For each model, we visually checked the heteroscedasticity
(which is the unequal variance of a variable across the range of
values of a second variable that predicts it) per group by plot-
ting residuals against the fitted values.
We corrected for multiple comparisons accounting for
the number of all the tests performed with the false-discovery
rate (FDR) method.
EFFECT OF MRI PROTOCOLS ON IMAGING MEASURES. To
assess the effect of the MRI protocol on MRI measures (we
took into account the protocols rather than the centers because
some centers acquired more than one protocol with more than
one scanner), we included it as a fixed-effect variable in a sepa-
rate mixed-effect model, and calculated the average effect sizes
for MRI protocols and MS phenotypes (ie, disease effects) while
fixing other variables.
ASSESSING ASSOCIATIONS BETWEEN BRAIN TISSUE VOL-
UMES AND DISABILITY ACCRUAL. For easier interpretation
of clinical and imaging measures, we standardized volumes by
subtracting the mean and dividing by the standard deviation
(SD; Z-score). We analyzed CIS and relapse-onset patients
together, because some patients had converted from CIS to
RRMS, or from RRMS to SPMS. This allowed us to take
advantage of a longer follow-up period. With similar mixed-
effects models, we investigated the following three questions:
(1) Are the baseline volumes of the DGM, the temporal,
frontal, parietal, occipital and cerebellar GM, brainstem, and
white matter, and white matter lesion load associated with
EDSS at baseline?; (2) Are changes in all these regional vol-
umes and white matter lesion load associated with EDSS
changes over time?; and (3) Do baseline volumes of all these
regions and white matter lesion at baseline predict time-to-
EDSS progression (event 5 EDSS progression) during fol-
low-up? The EDSS-progression event was defined as a 1.5
increase in EDSS, if the baseline EDSS was 0; 1-point
increase if EDSS was less than or equal to 6; and 0.5 increase
if EDSS was more than 6.42 We used a Cox regression model
to explore whether baseline volumes of these structures pre-
dicted time to event. We performed a post-hoc analysis using
all GM regions to determine the most important predictors
TABLE . Baseline Characteristics of Participants
Group Healthy
Controls
CIS RRMS SPMS PPMS
Total no. (no. of females) 203 (112) 253 (171) 708 (473) 128 (75) 125 (55)
Average follow-up
in years (range)
1.83 (0.5–7.8) 1.46 (0.5–13.0) 2.72 (0–13) 2.06 (0.0–5.5) 2.85 (0.5–6.0)
Average age (6 SD) 38.7 6 10.5 33 6 8 38.2 6 9.8 48.2 6 9.8 48.5 6 10.1
Average disease
duration (6 SD)
— 0.4 6 1.4 6.7 6 7.3 15.6 6 9.9 6.8 6 5.9
Median EDSS (range) — 1 (0.0–4.5) 2 (0–7) 6 (2.5–9.0) 5 (2–8)
Median T2 lesion load (ml)
(first–third quartiles)
— 2.97 (1.01–5.04) 5.05 (2.05–11.79) 11.04 (3.18–23.14) 9.38 (2.69–22.02)
% (no.) of patients on DMTs — 20 (52) 49 (345) 41 (52) 6 (8)
SD 5 standard deviation; CIS 5 clinically isolated syndrome; RRMS 5 relapsing-remitting multiple sclerosis; SPMS 5 secondary-progressive
multiple sclerosis; PPMS 5 primary-progressive multiple sclerosis; ml 5 milliliter; EDSS 5 expanded-disability status scale; DMTs 5 disease mod-
ifying treatments.
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FIGURE 2: Baseline volumes and annual percentage loss of brain regions in clinical phenotypes and healthy controls. Adjusted base-
line values for HCs, CIS, RRMS, SPMS, and PPMS are shown in (A), where the adjusted mean is shown as a point, and error bars show
the 95% confidence interval. Adjusted p values of pair-wise comparisons between groups are shown in Supplementary Table 4. Lon-
gitudinal analyses are shown in (B) and (C). Bar charts of the adjusted annual percentage of loss are shown in (B) for the predefined
regions. Height of each bar chart is the average estimate of the percentage annual loss from the mixed-effects model for each
group. Error bars represent 95% confidence interval of these estimates. Adjusted p values for pair-wise comparison between
regions across clinical phenotypes and HCs are shown in Supplementary Table 4. White matter volumes are not shown in (B) and (C)
because they did not show a significant change over time in any clinical phenotype. Post-hoc analyses of annual percentage loss are
shown in (C) where DGM nuclei, temporal, limbic, and default mode network regions were selected. Similar to (B), the adjusted aver-
age annual percentage volume loss for these regions is the height of each bar chart and error bars represent 95% confidence inter-
vals. Baseline values (A) and rates (B and C) were adjusted in a single mixed-effects hierarchical model including age, sex, total
intracranial volume at baseline, scanner magnetic field, and their interactions with time as the fixed effects. Center, subject and visits
were nested (hierarchical) random effects. HC 5 healthy controls; CIS 5 clinically isolated syndrome; RRMS 5 relapsing-remitting
multiple sclerosis; SPMS 5 secondary-progressive multiple sclerosis; PPMS 5 primary-progressive multiple sclerosis. [Color figure
can be viewed at www.annalsofneurology.org]
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of time-to-EDSS progression (as defined above) and confirm
that the results of the DGM were not affected by the bias of
merging a higher number of cortical regions into the main
lobes. We performed FDR correction to adjust for multiple
comparisons.
ADDITIONAL ANALYSES: SOFTWARE RELIABILITY AND
EFFECTS OF DISEASE-MODIFYING TREATMENTS. We car-
ried out additional analyses to assess the reliability of brain vol-
umes estimated with GIF software, FSL-FIRST, and SPM12,
and effects of treatments on atrophy measures. We also per-
formed area under the curve (AUC) analysis to examine the
prognostic accuracy of adjusted DGM volumes at individual
level (see Supplementary Material).
Results
MRI scans of 1,417 subjects were analyzed (scans of 3
subjects were excluded because of significant motion arte-
facts on visual inspection and 4 because of registration
issues because of missing MRI header information);
1,214 patients (253 had CIS, 708 had RRMS, 128 had
SPMS, and 125 had PPMS), and 203 were HCs. In
total, we analyzed 3,604 T1-weighted MRIs. Average
number of scans per subject was 2.54 (SD 5 1.04), with
an average follow-up of 2.41 years (SD 5 1.97) for
patients and 1.83 (SD 5 1.77) years for HCs (see the
Table for follow-up information per group). The total
numbers of participants with three or more visits for
each group were: 90 HCs, 48 CIS, 334 RRMS, 39
SPMS, and 58 PPMS. A total of 96 patients with CIS
(38%) converted to RRMS, and 28 patients with RRMS
(4%) converted to SPMS during the follow-up.
There was a significant difference in sex ratio
between groups (p < 0.001; see the Table for sex ratios).
Patients with progressive MS (SPMS and PPMS) had sig-
nificantly greater disability than patients with RRMS and
CIS (Mann–Whitney U tests, p < 0.001; see the Table)
and were older than RRMS (p < 0.001; average differ-
ence 5 10.7 years), CIS (p < 0.01; average difference 5
15.6 years), and HCs (p < 0.01, average difference 5 10
years). Age was similar between patients with RRMS and
HCs. Patients with CIS were younger than HCs (p <
0.01; average difference 5 4.9 years). Patients with CIS
had the lowest T2 lesion load, and patients with SPMS
had the highest T2 lesion load. Approximately half of
patients with RRMS were on disease-modifying treat-
ments (see the Table).
Brain Atrophy at Baseline in MS and Rates of
Volume Changes Over Time
At baseline, all clinical phenotypes (CIS, RRMS, SPMS,
and PPMS) had significantly smaller cortical GM and
DGM volumes than HCs. SPMS showed the lowest cor-
tical GM and DGM volumes, followed by PPMS,
RRMS, and CIS. All clinical phenotypes, but not CIS,
had significantly reduced whole brain and white matter
volumes when compared to HCs (see Fig 2A).
The fastest regional decline in tissue volume over
time was observed in the DGM in all clinical phenotypes
(PPMS: –1.66% per year; SPMS: –1.45%; RRMS: –
1.34%; CIS: –0.88%; p < 0.01) and in HCs (–0.94%).
Rate of atrophy in the DGM was greater in RRMS,
SPMS, and PPMS than CIS and HCs (all p values <0.01;
(Fig 2B; Supplementary Tables 3 and 4), but did not differ
between RRMS, SPMS, and PPMS. Rate of volume loss
in the DGM in all MS patients together was significantly
higher than that in the cortical and cerebellar GM and
brainstem (although the rate of volume loss over time in
these areas was still significant; all p values < 0.05).
Volume loss of the whole cortical GM was faster in
SPMS (–1.11% per year), PPMS (–0.79%), RRMS (–
0.67%), than HCs (–0.34%; all p values <0.05). Among
the cortical regions, the temporal lobe GM showed a
faster volume loss in SPMS (–1.21%) than RRMS (–
0.77%) and CIS (–0.75%; all p values <0.05; Fig 2B;
Supplementary Tables 3 and 4). Similarly, the parietal
GM showed a faster volume loss in SPMS (–1.24%)
than CIS (–0.63%; p < 0.05; Fig 2B; Supplementary
Tables 3 and 4). No differences in rates of volume loss
were observed in the frontal and occipital GM between
clinical phenotypes. Overall, all the cortical GM regions,
with the exception of the occipital cortex, showed a faster
rate of atrophy in MS than HCs (Fig 2B; Supplementary
Table 4).
The white matter did not show a significant rate of
volume loss in HCs or any of the clinical phenotypes.
There was no heteroscedasticity in the plots of
residuals against fitted values.
In the post-hoc analyses, when looking at regions
and clinical phenotypes, we found, that among the
DGM nuclei, the putamen showed the fastest volume
loss in PPMS (–2.6%). Within the temporal lobe GM,
the fastest volume loss was observed in the temporal pole
(–1.47%) and posterior insula in SPMS (–1.19%).
When looking at the parietal lobe GM, the precuneus
showed the fastest atrophy rates in SPMS (–1.28%; Fig
2C). Whereas the fastest rate of atrophy was observed in
the DGM in SPMS, the temporal lobe GM showed the
highest difference between SPMS and HCs (see Fig 2C).
There was no significant effect of sex on rates of
atrophy. There was no significant association between
GM volumes and T2 (or FLAIR) lesion load.
Regions Showing the Highest Rate of Loss
When we compared the rate of volume loss across differ-
ent regions in all patients (CIS, RRMS, SPMS, and
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PPMS) together, the fastest decline (or lowest slope) was
observed in the DGM (Supplementary Tables 3 and 4).
Rate of loss in the cortical GM regions was similar
between lobes and to that of the cerebellum. The slowest
rate of loss was observed in the brainstem.
Spatiotemporal Pattern of GM Volume Loss in
Clinical Phenotypes
Although SPMS showed the lowest baseline volumes of
cortical GM and DGM, and the rate of the DGM vol-
ume loss was faster in SPMS, PPMS, and RRMS than
CIS and HCs, there was no significant association
between rate of loss in specific regions and clinical phe-
notypes, which suggests that all clinical phenotypes share
a similar spatiotemporal pattern of GM loss.
Effect of MRI Protocols on Imaging Measures
The average effects of MS phenotypes on brain volumes
at baseline were higher than the protocol effect on the
brain volumes (protocol effects: whole brain 5 4.3%;
cortical GM 55.1%; DGM 5 8.5%; disease effects:
whole brain 5 4.8%; cortical GM 5 5.2%; DGM 5
13.7%). Average effects of MS phenotypes were higher
than the effects of protocol on the rates of atrophy of the
cortical GM and DGM (protocol effects: cortical GM 5
0.14%; DGM 5 0.21%; disease effects: cortical GM 5
0.57%; DGM 50.53%), but not those of the whole
brain (protocol effect 5 0.51%; disease effect 5 0.38%).
Association Between EDSS and GM Loss
In all clinical phenotypes combined, lower DGM and
cortical GM volumes at baseline were associated with
higher disability, as measured by the EDSS (DGM b 5
–0.71, p < 0.0001; cortical GM b 5 –0.22; p<0.0001).
Under the assumption of a linear relationship between
EDSS and GM volume, this suggests that for every Z-
score decrease in the DGM and cortical volume at base-
line, the baseline EDSS increased on average by 0.7 and
0.22, respectively.
There was a significant progression of EDSS in
both relapse-onset and PPMS patients, which on average
increased by 0.07 and 0.2 per year, respectively. When
we examined associations between the rate of EDSS
changes and rate of changes in the volumes of cortical
GM regions, cerebellar GM, and DGM over time, only
the rate of loss in the DGM was associated with
FIGURE 3: DGM volume predicts future progression of EDSS. Survival curves for time to event (sustained EDSS progression;
see Patients and Methods for definition) in CIS, relapse onset, and PPMS. We have analyzed CIS and relapse-onset patients
together because a proportion of patients convert from CIS to RRMS, or from RRMS to SPMS, during the course of study. Haz-
ard ratios for models with continuous outcome variables (regional volumes) are reported. DGM 5 deep gray matter; EDSS 5
Expanded-Disability Status Scale; HC, healthy controls; CIS, clinically isolated syndrome; RRMS, relapsing-remitting multiple
sclerosis; SPMS, secondary-progressive multiple sclerosis; PPMS, primary-progressive multiple sclerosis; HR 5 hazard ratio;
CI 5 confidence interval. [Color figure can be viewed at www.annalsofneurology.org]
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disability accumulation (b 5 –0.04; 95% confidence
interval [CI], –0.02, –0.06; p 5 0.006). Under the
assumption of a linear relationship between EDSS and
rate of GM volume loss over time, this suggests that
every SD (Z-score) loss in the rate of DGM volume cor-
responded to an annual EDSS gain of 0.04.
The percentage of patients who had EDSS progres-
sion during follow-up (or who experienced the “event”)
was 26%. When we looked at baseline predictors of dis-
ability accumulation, without any longitudinal imaging
measure in the model, only the DGM predicted future
EDSS progression. The hazard ratio (95% CI, p value) for
time-to-EDSS progression was 0.73 (95% CI, 0.65, 0.82;
p < 0.0001), which suggests that, for every SD (Z-score)
decrease in the DGM volume at baseline, the risk of pre-
senting a shorter time to EDSS worsening during the
follow-up increased by 27% (95% CI, 18–35]. The hazard
ratio remained similar when we analyzed relapse-onset and
PPMS patients separately (0.72 and 0.73, respectively). Fig-
ure 3 illustrates the survival curve for these analyses.
In the post-hoc analyses, baseline thalamic volume
had the highest predictive value of EDSS progression
FIGURE 4: Risk of EDSS progression during follow-up for each Z-score volume loss of the brain regions at baseline (post-hoc anal-
ysis). Results of the post-hoc Cox proportional hazards univariate models are shown for the time-to-event analyses (event 5 sus-
tained EDSS worsening; see Patients and Methods for the definition) in the regions of Neuromorphometrics’ atlas, which are
shown in (A). The predictors were the baseline volumes of the regions shown in the x-axes of (B) for CIS, RRMS, and SPMS and (C)
for PPMS. CIS, RRMS, and SPMS were analyzed together because several patients convert from one phenotype to another. Brain
maps are shown in the left column, and bar charts of the same analyses are shown in the right column of (B) and (C). Only regions
whose p value of the survival analysis survived FDR correction (adjusted p < 0.05) are shown in (B) and (C). The y-axes show the
risk of progression for each Z-score loss in the volume of the corresponding brain region on x-axes. For example, for every Z-score
loss of the thalamus volume at baseline, the risk of EDSS worsening during follow-up increased by 37% for the CIS, RRMS, and
SPMS group and 40% for PPMS. Color maps code the importance of baseline volumes of the regions to predict EDSS worsening
(or EDSS progression) during follow-up. The absolute values of coefficients for ventricular volumes are shown in (B), because they
have an effect in the opposite direction of other structures. Error bars indicate the 95% confidence intervals. EDSS 5 Expanded-
Disability Status Scale; HC, healthy controls; CIS, clinically isolated syndrome; RRMS, relapsing-remitting multiple sclerosis; SPMS,
secondary-progressive multiple sclerosis; PPMS, primary-progressive multiple sclerosis. [Color figure can be viewed at www.
annalsofneurology.org]
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during follow-up in both PPMS and the relapse-onset
groups, by increasing the risk to a shorter time to EDSS
worsening of 37% in relapse-onset MS and 40% in
PPMS (Fig 4B,C). In this analysis, the predictive value
of the thalamus was followed by that of the hippocampus
and angular gyrus in relapse-onset MS (Fig 4B), and by
that of the putamen, posterior insula, and temporal pole
in PPMS (Fig 4C).
There were no significant differences in rates of loss
in patients who were receiving disease-modifying drugs
and those who were not (see Supplementary Text). Anal-
yses with GIF software, FSL-FIRST, and SPM12 con-
firmed the reliability of brain volumes estimates (see
details in Supplementary Text). AUC analysis showed
that DGM volumes were similar to a random classifier
in prognosticating individual patients (see details in Sup-
plementary Text).
Discussion
In this large, multicenter study, we have shown that vol-
ume loss in DGM over time was faster than that observed
in other brain regions across all clinical phenotypes, and
DGM volume loss was the only GM region associated
with disability accumulation. Additionally, we found that
the smaller DGM volume at baseline was associated with
increased risk of shorter time to EDSS progression, in
agreement with previous studies that showed smaller
DGM volume associated with higher disability.14,15 Inter-
estingly, we found that atrophy rates of the GM of cortical
lobes were the fastest in SPMS, and were faster in the tem-
poral lobe in SPMS in comparison with RRMS and CIS
and in the parietal lobe in SPMS in comparison to CIS.
However, no significant association between cortical
regions and disability progression was detected. Overall,
our findings suggest that the development of DGM atro-
phy may drive disability accumulation irrespective of clini-
cal phenotypes, thereby becoming a useful outcome
measure in neuroprotective clinical trials. Although the
spatiotemporal pattern of atrophy remains similar across
MS phenotypes, some cortical regions show accelerated
atrophy in SPMS than RRMS and/or CIS. We now discuss
these results in turn and in detail.
The pathological events that underpin DGM atro-
phy are not known, but this is generally interpreted as the
result of neurodegeneration. Previous studies have shown
that DGM atrophy is more severe in patients with progres-
sive MS, longer disease duration, and worse cognitive per-
formance.14,15,43 Our post-hoc analyses showed that the
thalamus, which is the DGM’s largest component, was a
better predictor of future disability than other regions, and
the rate of atrophy in the putamen was the highest across
DGM nuclei. Previous studies, including those using
advanced MRI, have found that thalamic damage at study
entry was associated with higher disability.13–15 DGM
structures are extensively connected with cortical GM
regions, and therefore DGM atrophy could be attributed
to retrograde and anterograde neurodegeneration through
tracts that connect GM areas. For example, the extent of
cellular density loss in the thalamus is associated with neu-
rodegeneration in the remote (but connected) cortical
regions, over and beyond the extent of atrophy explained
by demyelination in connecting tracts.44 There is also evi-
dence of other neurodegenerative mechanisms in the
DGM nuclei. For example, their higher load of iron than
other regions can accumulate oxidised lipids, which are
associated with neurodegeneration.45 In our healthy con-
trols, rate of DGM atrophy was faster than that in other
regions, suggesting that it may be a hotspot for both age-
and disease-related atrophy in the human brain, although
a methodological issue, related to its more uniform struc-
ture than other brain regions, cannot be excluded. In AUC
analysis, we found that, at the individual level, DGM vol-
ume lacks prognostic value, which is attributed to the high
variability typical of volumetric MRI studies.46 Neverthe-
less, the DGM volume holds strong promise as a marker
of disease progression (at the group level) with the poten-
tial to respond to neuroprotective treatments that target
neurodegeneration in MS.
Interestingly, the temporal lobe showed a significant
acceleration in SPMS when compared to both RRMS
and CIS. Similarly, the parietal lobe GM showed a sig-
nificant acceleration of atrophy in SPMS in comparison
to CIS. Our post-hoc analysis showed that the temporal
pole and insula were the most affected structures in the
temporal GM. Pathological studies have demonstrated an
increase in the rate of neurodegeneration, especially in
the temporal regions, during progressive stages of MS in
comparison to RRMS and CIS.47,48 Overall, a global
pathological process in MS49 may become more pro-
nounced in certain regions, such as the temporal GM,
because of other mechanisms, such as static exposure to
CSF (the insula in the temporal lobe) or hypoxia in
watershed areas (some DGM nuclei such as the pal-
lidum). For example, meningeal inflammation and corti-
cal demyelination, which may play a role in cortical
atrophy, preferentially affect deep sulci, such as the
insula, where there is more exposure to static inflamma-
tory cytokines.2 Our findings also suggest that regions
with more connections may be vulnerable to atrophy.
For example, among the parietal cortical regions, the pre-
cuneus, a core part of an important functional brain net-
work (default mode network), showed the fastest atrophy
rates in SPMS.39 Thus, acceleration of atrophy during
SPMS may be explained by cortical network collapse
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with advancing of degeneration from initial injury sites
(focal lesions in the white matter or initial DGM degen-
eration) to interconnected neocortical systems.50 We
found that MS phenotypes shared a common spatiotem-
poral pattern of volume loss (no significant three-way
interaction of time 3 region 3 phenotype). This shows,
in line with previous studies, that the difference in
pathology of progressive MS is only quantitative rather
than qualitative in comparison to RRMS.2,51
Cortical GM atrophy was observed at study entry
across clinical phenotypes, even in CIS, when compared
to HCs, and was the greatest in progressive MS, in agree-
ment with earlier studies.17,52 Our findings of faster
whole brain atrophy in SPMS, PPMS, and RRMS than
CIS, who, in turn, showed higher cortical atrophy than
HCs, are similar to previous studies on longitudinal
whole brain atrophy,5,53,54 regional atrophy,17,55–57 and
pathology of MS phenotypes,2,47 Our study confirms our
previous findings that relationships between whole brain
atrophy and clinical changes are weak or absent5 and
shows DGM atrophy as a stronger marker of clinical dis-
ability. Although the GM volumes of cortical lobes could
not predict future EDSS progression, the more detailed
post-hoc analyses showed that regional volumes, such
those of the hippocampus and the angular gyrus, were
associated with future EDSS progression. These regions
are highly connected to other regions, and especially the
angular gyrus (like the precuneus) acts as a hub in the
default mode network, which could make it vulnerable
to atrophy, as explained above.39
This study was not designed to assess the effect of
treatment on atrophy rates, but does study atrophy while
adjusting for possible confounding effects. The rates of
atrophy in all clinical phenotypes were similar in people
who were receiving disease-modifying treatments to those
who were not. Even though we could not ascertain the
duration of treatments attributed to retrospective nature
of this study, the majority (90%) of patients on disease-
modifying treatments were receiving first-line injectable
drugs (interferon or glatiramer acetate) before study
entry. The effects of these drugs on brain atrophy are
modest at best.58,59 Therefore, drug effects are unlikely
to be confounders of our analysis.
One strength of our study is that we included a large
number of patients, who underwent the same protocol on
the same MRI scanner over time at single sites. However,
different MRI protocols could have an effect on atrophy
measures and is a limitation of our study.60,61 We therefore
used a hierarchical statistical design based on scanner. Our
study was powerful enough because the effects of clinical
phenotype on the regional rates of atrophy were higher
than the effects of between-center variation.
We chose GIF software to segment and parcellate
the brain31 because it allowed inclusion of two-
dimensional MRI data (which we had for one center),
and did not require any manual editing, unlike Freesur-
fer, which would have been unfeasible for such large
number of scans. Our reliability analysis showed excellent
agreement between GIF-derived DGM volume and that
obtained using FSL-FIRST, and between GIF-derived
cortical volumes and those obtained using SPM12,
respectively. Therefore, we chose to present the results
obtained with GIF because it allowed us to rely on only
one method to segment DGM and cortical GM, and
estimate total intracranial volume (TIV). We used TIV
to adjust for variations in head size, rather than the skull
size, so that a more reliable estimate of head size was
obtained, irrespectively of the field of view, the choice of
the inferior cutoff of the brain for the analysis, and
demographic factors (eg, age, weight).62 With regard to
the statistical methods, we used mixed-effects models to
calculate atrophy rates,41 which naturally accommodated
multiple (three or more) time points with varying inter-
vals between follow-ups, and patients who convert from
one phenotype to another (eg, CIS to RRMS). These
two issues are cumbersome to address with methods that
rely on pairwise comparisons (eg, SIENA, BSI) and suf-
fer from higher variance in brain atrophy estimates as the
interval between two scans increases.63,64 Mixed-effects
modeling, instead, estimates a variance component to
eliminate implausible inconsistencies.65,66 Based on our
experience and the results of this study, we recommend
the acquisition of high-resolution 3D-T1 images (isotro-
pic 1mm3). Several methods can calculate DGM vol-
umes, such as FSL-FIRST and GIF. We recommend the
use of the GIF software when it is desirable to use the
same method to segment both the cortex and DGM.
There were also limitations in this study. The
majority of centers did not provide MRI scans of HCs;
however, we included a large number of HCs including
those from an external initiative (PPMI). Our findings of
volume changes in HCs were consistent with the litera-
ture. Meta-analyses have shown, in individuals aged <70
years, rate of whole brain loss ranges from 0 to –0.5 (our
study 5 –0.04), GM loss ranges from 0% to –0.5% per
year (cortical GM in our study 5 –0.34%),67 and the
subcortical structures may show loss of up to –1.12%
(DGM in our study 5 –0.94).68 Cognitive functions
were not tested, and it is unknown whether cortical pat-
terns of GM atrophy over time were associated with cog-
nitive impairment. Clinical trials in MS (and in
progressive MS in particular) include confirmed disability
progression, based on the EDSS, as a primary outcome
measure. Although for EDSS the model-estimated
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coefficients and their p values and confidence intervals
are valid for comparison between brain regions, the abso-
lute value of these coefficients must be interpreted with
caution, because the EDSS does not have a uniform lin-
ear interpretation. Because this was a retrospective study,
the duration of treatments before entry to the study
could not be ascertained for all participants. Disease-
modifying drugs may have lasting effects; for example,
they may slow the accrual of disability after a decade.59,69
Moreover, MRI sequences sensitive to cortical lesions
were not available, and the effects of cortical lesions on
atrophy measures remain unknown.
In conclusion, DGM atrophy showed the most
rapid development over time—extending previous cross-
sectional studies that showed a relationship between
DGM atrophy and disability—was most closely associ-
ated with disability accumulation and predicted the time
to EDSS worsening. In phase II trials of neuroprotective
medications in MS, DGM atrophy measures may there-
fore have greater potential to show treatment effects than
other regional GM or whole brain measures. There was a
disconnect between DGM atrophy and cortical atrophy
rates. Temporal and parietal cortices showed a faster rate
of atrophy in SPMS than RRMS and/or CIS, whereas
DGM showed a faster rate of atrophy in SPMS than CIS
only, suggesting that neurodegeneration in GM regions
may proceed at a different rate which should be taken
into account in the design of clinical trials.
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